



## **Intraoperative Fluorescence Diagnostic Systems**

# Intra-operative Immunophotodetection (IPD) of cancers

---

## Unmet medical need :

**Diagnosis tool** for superficial carcinomas of infra-clinical size, that are responsible for **loco-regional relapses** in digestive and ovarian cancers.



## ➤ Colorectal cancer :



- 945 000 new cases / year in the world
- 492 000 deaths
- Surgery in 80 % of patients

➤ Reach a **better analysis and grading** of the disease to orient the post-surgery therapeutic protocol in the best possible way for each patient.

➤ Develop a **new medical imaging** technique that allows surgeons to **visualize in real-time** the tumor cells during surgery.

➤ Complete a **total resection** of cancer nodules.

**The technique can be used for all patients entering surgery with this type of pathology.**



# SurgiMab : the company

## The team

---


- CEO, CSO, founder: Dr. Françoise Cailler.
  - Engineer **INSA Tlse**/ Ph.D. in Biochemistry **U. de Montréal**
  - Industrial experience (Neurotech, Diatos, ..., BioRéalités)
  
- CFO, founder: Mr. Michel Barbelanne
  - Degree in Immunology, **UPS-Tlse**/ Master in Management of Innovation and Technology, **Tlse Business School**
  - Industrial Experience (Matbiopharma)
  
- Scientific expert, founder: Dr. André Pèlegriin
  - Head of **Institut de Recherche en Cancérologie de Montpellier (IRCM)**
  - DR2 INSERM - Conception, development and *in vivo* use of antibodies and derived molecules for diagnosis and therapy of cancers.
  
- Medical expert, founder: Dr. Marian Gutowski
  - Oncology surgeon in **Montpellier CRLC** (Comprehensive Research Center).
  - Origin of the intra-operative optical device - involved in the clinical studies.

# SurgiMab

## Resume

---

- Advanced R&D with prestigious partners
- Obvious medical interest
- Positive informal safety results on the conjugate
- Multidisciplinary team with experience - complementarity of the members of the team
- Surgeon involved from the early beginning
- Project and company both integrated within the hospital at CRLC
  - ✓ Simplification of clinical assays
  - ✓ Easy access to an important network of opinion leaders that will facilitate the spreading of the technology
- Good opportunity for a quick medical development
- Attractive return on investment



**SurgiMab**

Visit our website  
[www.surgimab.com](http://www.surgimab.com)